Type 2 Diabetes Mellitus Therapeutics Market 2022 Type 2 Diabetes Mellitus Therapeutics Market 2022 | Page 5

3.5.2 Bydureon (exenatide) - AstraZeneca 49
3.5.3 Victoza (liraglutide) - Novo Nordisk 50
3.5.4 Lyxumia (lixisenatide) - Sanofi 52
3.5.5 Tanzeum (albiglutide) - GlaxoSmithKline 53
3.6 DPP-4 Inhibitors 54
3.6.1 Januvia (sitagliptin) - Merck 54
3.6.2 Galvus (vildagliptin) - Novartis 55
3.6.3 Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca 57
3.6.4 Trajenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca 58
3.6.5 Zemiglo (gemigliptin) - LG Life Sciences 59
3.6.6 Suganon (evogliptin) - Dong-A ST 59
3.6.7 Gadret (anagliptin) - JW Pharmaceutical 60
3.6.8 Nesina (alogliptin) - Takeda 61
3.6.9 Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma 61
3.7 SGLT-2 Inhibitors 62
3.7.1 Forxiga (dapagliflozin) - AstraZeneca 62
3.7.2 Invokana (canagliflozin) - Janssen 63
3.7.3 Jardiance (empagliflozin) - Boehringer Ingelheim 64
3.7.4 Suglat (ipragliflozin) - Astellas 65
3.8 Insulin Therapies 66
3.8.1 Lantus (insulin glargine) - Sanofi 66
3.8.2 Levemir (insulin detemir) - Novo Nordisk 67
3.8.3 Tresiba (insulin degludec) - Novo Nordisk 67
3.8.4 Toujeo (insulin glargine) - Sanofi 68
3.9 Comparative Efficacy and Safety of Marketed Products 69
Follow Us: